more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

Top 35% (89 out of 251)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Add NextGen Stock to Your Portfolio Now

by Zacks Equity Research Published on August 19,2020

Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.

medical

PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol

by Zacks Equity Research Published on August 19,2020

PerkinElmer's (PKI) Hand Sanitizer Analyzer can help lab professionals and scientists all over the world in their fight against COVID-19.

medical

PerkinElmer Launches Workstations for Coronavirus Testing

by Zacks Equity Research Published on August 18,2020

PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process of SARS-CoV-2 RT-PCR testing.

medical

Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

by Zacks Equity Research Published on August 17,2020

The FDA approval of Masimo's (MASI) PVi system will enable patient safety.

medical

Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on August 10,2020

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.

SurModics (SRDX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research Published on August 05,2020

SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

SRDXPositive Net Change

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on July 29,2020

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRDXPositive Net Change

Here's Why You Should Add AMN Healthcare to Your Portfolio

by Zacks Equity Research Published on July 24,2020

Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.

medical

Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline

by Zacks Equity Research Published on July 22,2020

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRDXPositive Net Change

PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis

by Zacks Equity Research Published on July 22,2020

PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.

medical

Masimo (MASI) Introduces Automation and Connectivity Solution

by Zacks Equity Research Published on July 15,2020

Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.

medical

Here's Why You Should Retain Merit Medical (MMSI) for Now

by Zacks Equity Research Published on July 15,2020

Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.

medical

VREX vs. SRDX: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on July 14,2020

VREX vs. SRDX: Which Stock Is the Better Value Option?

QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results

by Zacks Equity Research Published on July 13,2020

Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.

medical

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research Published on July 10,2020

Investor confidence is high on Nevro (NVRO), thanks to solid prospects

medical

BD Unveils BD PurPrep Patient Preoperative Skin Preparation

by Zacks Equity Research Published on July 08,2020

By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.